West Pharmaceutical Services (WST) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" WST shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WST, but not buy additional shares or sell existing shares.
View WST analyst ratings or view top-rated stocks.

5 Wall Street research analysts have issued 12 month price objectives for West Pharmaceutical Services' stock. Their WST share price forecasts range from $250.00 to $400.00. On average, they anticipate the company's stock price to reach $313.00 in the next year. This suggests that the stock has a possible downside of 8.9%.
View analysts price targets for WST or view top-rated stocks among Wall Street analysts.

West Pharmaceutical Services' stock was trading at $235.35 on January 1st, 2023. Since then, WST stock has increased by 46.1% and is now trading at $343.73.
View the best growth stocks for 2023 here.

West Pharmaceutical Services saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 863,800 shares, a drop of 27.4% from the April 30th total of 1,190,000 shares. Based on an average trading volume of 464,600 shares, the days-to-cover ratio is presently 1.9 days. Currently, 1.2% of the shares of the company are short sold.
View West Pharmaceutical Services' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our WST earnings forecast.

West Pharmaceutical Services, Inc. (NYSE:WST) posted its quarterly earnings data on Thursday, April, 27th. The medical instruments supplier reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.31. The medical instruments supplier earned $716.60 million during the quarter, compared to the consensus estimate of $697.28 million. West Pharmaceutical Services had a net margin of 19.15% and a trailing twelve-month return on equity of 24.14%. West Pharmaceutical Services's quarterly revenue was down .5% compared to the same quarter last year. During the same quarter last year, the company posted $2.30 EPS.
Read the conference call transcript.

West Pharmaceutical Services declared a quarterly dividend on Thursday, April 27th. Stockholders of record on Wednesday, July 26th will be given a dividend of $0.19 per share on Wednesday, August 2nd. This represents a $0.76 annualized dividend and a yield of 0.22%. The ex-dividend date of this dividend is Tuesday, July 25th.
Read our dividend analysis for WST.

ETFs with the largest weight of West Pharmaceutical Services (NYSE:WST) stock in their portfolio include Invesco Dynamic Market ETF (PWC), Nuveen ESG Mid-Cap Growth ETF (NUMG), BlackRock Future Health ETF (BMED), First Trust Indxx Medical Devices ETF (MDEV), Invesco S&P 500 GARP ETF (SPGP), Siren DIVCON Leaders Dividend ETF (LEAD), BlackRock Future Innovators ETF (BFTR) and FT Cboe Vest S&P 500 Dividend Aristocrats Target Income ETF (KNG).

West Pharmaceutical Services (NYSE:WST) pays an annual dividend of $0.76 per share and currently has a dividend yield of 0.22%. The company has been increasing its dividend for 30 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 10.44%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, WST will have a dividend payout ratio of 8.78% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for WST.

West Pharmaceutical Services issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided earnings per share guidance of $7.50-$7.65 for the period, compared to the consensus EPS estimate of $7.42. The company issued revenue guidance of $2.96 billion-$2.99 billion, compared to the consensus revenue estimate of $2.96 billion.

107 employees have rated West Pharmaceutical Services Chief Executive Officer Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 75% among the company's employees. 60.0% of employees surveyed would recommend working at West Pharmaceutical Services to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.81%), Bank of New York Mellon Corp (4.81%), State Street Corp (4.43%), Price T Rowe Associates Inc. MD (3.83%), Franklin Resources Inc. (3.08%) and Geode Capital Management LLC (2.08%). Insiders that own company stock include Annette F Favorite, Charles Witherspoon, David A Montecalvo, Eric Mark Green, George Lloyd Miller, Patrick J Zenner, Quintin J Lai, Silji Abraham and Thomas W Hofmann.
View institutional ownership trends.

Shares of WST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WST stock can currently be purchased for approximately $343.73.

West Pharmaceutical Services (NYSE:WST) has a market capitalization of $25.52 billion and generates $2.89 billion in revenue each year. The medical instruments supplier earns $585.90 million in net income (profit) each year or $7.28 on an earnings per share basis.

The company employs 13,550 workers across the globe.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The official website for the company is www.westpharma.com. The medical instruments supplier can be reached via phone at (610) 594-2900, via email at quintin.lai@westpharma.com, or via fax at 800-345-9800.